leisure time -WSS

leisure time

author：entertainment 2025-10-01 22:58:11 - browse：78752

Bill Cassidy speaks with his palm facing upward during a hearing on prescription drug costs — politics coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — Republicans in Congress might try to use a technical maneuver to block the Biden administration from using so-called march-in rights to seize pharmaceutical patents and lower drug prices.

The Biden White House wants to ignore certain patents for inventions that were developed with government funding, at least in extenuating circumstances. Taxpayers have helped fund the research of a substantial number of drugs sold in the United States though the National Institutes of Health, so the proposal would let the government bring in generic drugmakers to make medicines even before their patents expire.

Until the Biden administration, the government refused to consider that an invention’s price could justify the “march in” maneuver. But the White House in December issued a draft framework for the NIH to more broadly use the power, including in cases where price is a concern.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Tori Bowie and the unacceptable rates of Black maternal death

focus

hotspot

WSS

NIH study of ME/CFS points to clear biological hallmarks

Novavax promises a turnaround & Lilly roils the obesity market

The Harvard botanist who searched for psychedelics in the Amazon

Moonlake's readout produced a cash windfall. Risks remain

Hepatitis C has a cure — but many Americans still lack access to it

Activists slam private health insurers over coverage restrictions

explore

leisure time

knowledge

At least 13 dead in Texas as scorching temps continue

United colonoscopy coverage change 'may cost lives,' doctors say

Apple is now the first public company to be valued at $3 trillion

PBM reform efforts get punted in Congress

Activists slam private health insurers over coverage restrictions

He's a Nobel laureate. Critics say he was misleading on Covid

Moonlake's readout produced a cash windfall. Risks remain

Dario to buy mental health app maker Twill in cash and stock deal

BioMarin wins approval for gene therapy to treat hemophilia A

Alabama hospital puts IVF treatments on hold

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Ed Silverman on new gene therapies, biosimilars, coffee, and more

The high cost of giving birth even with insurance

The Harvard botanist who searched for psychedelics in the Amazon

He's a Nobel laureate. Critics say he was misleading on Covid

Apple is now the first public company to be valued at $3 trillion

hotspot

focus

hotspot

hotspot